Sumitomo Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 11%, Exceeded Record Profit Forecast

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Mon Mar 2, 2026 3:40 pm JST Revision

4506 Sumitomo Pharma Co., Ltd. 【IFRS】

Guidance Update Report

Sumitomo Pharma Co., Ltd. <4506> [TSE Prime] announced a performance revision after the market closed on March 2nd (15:40). The consolidated net income forecast for the fiscal year ending March 2026 has been revised upward 10.9%, from the previous forecast of 92.0 billion yen to 102 billion yen (compared to 23.6 billion yen in the previous period), increasing the growth rate from 3.9 times to 4.3 times. The company has further increased its previous forecast of record profits for the first time in four years.

Based on the upwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (second half) consolidated net income has been revised upward from an expected loss of 6.86 billion yen to a profit of 3.14 billion yen (compared to a profit of 55.8 billion yen in the same period of the previous year), turning to a profit.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2025 Prev	201,878	1,843	ー	-6,860	-17.3	0	Oct 31, 2025	IFRS
Oct - Mar, 2025 New	221,878	11,843	ー	3,140	7.9	0	Mar 2, 2026	IFRS
Revision Rate	+9.9%	+542.6%	－	－	－

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2026 Prev	429,000	98,000	ー	92,000	231.6	0	Oct 31, 2025	IFRS
Mar, 2026 New	449,000	108,000	ー	102,000	256.7	0	Mar 2, 2026	IFRS
Revision Rate	+4.7%	+10.2%	－	+10.9%	+10.9%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024	218,083	36,983	50,017	55,863	140.6	0	May 13, 2025	IFRS
Oct - Mar, 2025 Guidance	221,878	11,843	ー	3,140	7.9	0	Mar 2, 2026	IFRS
YoY	+1.7%	-68.0%	－	-94.4%	-94.4%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2024	314,558	-354,859	-323,114	-314,969	-792.8	0	May 14, 2024	IFRS
Mar, 2025	398,832	28,804	17,611	23,634	59.5	0	May 13, 2025	IFRS
Mar, 2026 Guidance	449,000	108,000	ー	102,000	256.7	0	Mar 2, 2026	IFRS
YoY	+12.6%	+274.9%	－	+331.6%	+331.6%